Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

CRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics cleared that benchmark Wednesday, with a jump from 69 to 89 Wednesday.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.

Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.

Looking For Winning Stocks? Try This Simple Routine

Now is not an ideal time to jump in since it isn't near a proper buy zone after blasting higher on numbers from the recent earning release. Best to wait for some consolidating and then see if the stock is able to establish a new pattern, then enter a buy zone in heavy trade.

The company reported 0% earnings growth in the latest quarterly report, however sales growth came in at a whopping 10,538%.

CRISPR Therapeutics holds the No. 61 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics is also among the group's highest-rated stocks.

​Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.